Literature DB >> 8437006

Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis.

M K Sharief1, E J Thompson.   

Abstract

Concentrations of interleukin-2 (IL-2) and soluble IL-2 receptor (sIL-2R) in serum and CSF samples were measured in 63 patients with multiple sclerosis (MS) to evaluate their usefulness as markers of disease activity. CSF concentrations of IL-2 and sIL-2R were significantly higher in MS relapse compared with MS patients in remission or with control subjects. These concentrations correlated with the clinical score by which disease severity was assessed, with the number of relapses per year, and with the total disease duration. Furthermore, there was evidence of intrathecal release of IL-2 and sIL-2R in clinically active MS. The results extend the notion that an activated cellular immune state parallels the evolution of the pathological process in MS and suggest that measurement of IL-2 and sIL-2R concentrations may provide an objective marker of disease activity in patients with MS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437006      PMCID: PMC1014817          DOI: 10.1136/jnnp.56.2.169

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  35 in total

1.  Multiple sclerosis: increased expression of interleukin-2 receptors on lymphocytes.

Authors:  K Selmaj; C Plater-Zyberk; K A Rockett; R N Maini; R Alam; G D Perkin; F C Rose
Journal:  Neurology       Date:  1986-10       Impact factor: 9.910

2.  Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.

Authors:  A S Rose; J W Kuzma; J F Kurtzke; N S Namerow; W A Sibley; W W Tourtellotte
Journal:  Neurology       Date:  1970-05       Impact factor: 9.910

3.  Elevated levels of soluble interleukin-2 receptors in multiple sclerosis.

Authors:  S J Greenberg; L Marcon; B J Hurwitz; T A Waldmann; D L Nelson
Journal:  N Engl J Med       Date:  1988-10-13       Impact factor: 91.245

4.  Calculating confidence intervals for some non-parametric analyses.

Authors:  M J Campbell; M J Gardner
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

5.  Measurement of IgG and albumin content of cerebrospinal fluid, and its interpretation.

Authors:  K Ganrot; C B Laurell
Journal:  Clin Chem       Date:  1974-05       Impact factor: 8.327

6.  Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients.

Authors:  P Gallo; M Piccinno; S Pagni; B Tavolato
Journal:  Ann Neurol       Date:  1988-12       Impact factor: 10.422

Review 7.  Interleukin-2: inception, impact, and implications.

Authors:  K A Smith
Journal:  Science       Date:  1988-05-27       Impact factor: 47.728

8.  In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.

Authors:  M K Sharief; R Hentges; M Ciardi; E J Thompson
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

9.  Soluble IL-2 receptors in acute and subacute encephalitis.

Authors:  B Boutin; L Matsuguchi; P Lebon; G Ponsot; M Arthuis; D L Nelson
Journal:  Ann Neurol       Date:  1987-11       Impact factor: 10.422

10.  Effects of cyclosporin A on expression of IL-2 and IL-2 receptors in normal and multiple sclerosis patients.

Authors:  V L Calder; A S Bellamy; S Owen; C Lewis; P Rudge; A N Davison; M Feldmann
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

View more
  9 in total

Review 1.  Multiple Sclerosis and T Lymphocytes: An Entangled Story.

Authors:  Laurine Legroux; Nathalie Arbour
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-07       Impact factor: 4.147

2.  Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients.

Authors:  S Inogés; J Merino; E Bandrés; P De Castro; M L Subirá; A Sánchez-Ibarrola
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

3.  A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis.

Authors:  Nathalie Arbour; Andreas Holz; Jack C Sipe; Denise Naniche; John S Romine; Jack Zyroff; Michael B A Oldstone
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

4.  Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis.

Authors:  B Fellay; M Chofflon; C Juillard; A M Paunier; T Landis; S Roth; M L Gougeon
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

5.  IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis.

Authors:  Marko Petržalka; Eva Meluzínová; Jana Libertínová; Hana Mojžišová; Jitka Hanzalová; Petra Ročková; Martin Elišák; Silvia Kmetonyová; Jan Šanda; Ondřej Sobek; Petr Marusič
Journal:  PLoS One       Date:  2022-06-27       Impact factor: 3.752

6.  CD4+CD28- costimulation-independent T cells in multiple sclerosis.

Authors:  S Markovic-Plese; I Cortese; K P Wandinger; H F McFarland; R Martin
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 7.  The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis.

Authors:  Daphne Peerlings; Max Mimpen; Jan Damoiseaux
Journal:  J Transl Autoimmun       Date:  2021-09-21

8.  Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjögren's syndrome.

Authors:  Magdalena Keindl; Richard Davies; Brith Bergum; Johan G Brun; Daniel Hammenfors; Roland Jonsson; Valeriya Lyssenko; Silke Appel
Journal:  Arthritis Res Ther       Date:  2022-05-07       Impact factor: 5.606

9.  Increased Plasma Soluble Interleukin-2 Receptor Alpha Levels in Patients With Long-Term Type 1 Diabetes With Vascular Complications Associated With IL2RA and PTPN2 Gene Polymorphisms.

Authors:  Magdalena Keindl; Olena Fedotkina; Elsa du Plessis; Ruchi Jain; Brith Bergum; Troels Mygind Jensen; Cathrine Laustrup Møller; Henrik Falhammar; Thomas Nyström; Sergiu-Bogdan Catrina; Gun Jörneskog; Leif Groop; Mats Eliasson; Björn Eliasson; Kerstin Brismar; Peter M Nilsson; Tore Julsrud Berg; Silke Appel; Valeriya Lyssenko
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-30       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.